1. Home
  2. AMS vs KPRX Comparison

AMS vs KPRX Comparison

Compare AMS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

HOLD

Current Price

$1.34

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.34

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMS
KPRX
Founded
1980
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
8.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
AMS
KPRX
Price
$1.34
$2.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
111.7K
619.3K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,714,000.00
N/A
Revenue This Year
$6.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.81
N/A
52 Week Low
$1.25
$1.76
52 Week High
$3.11
$4.18

Technical Indicators

Market Signals
Indicator
AMS
KPRX
Relative Strength Index (RSI) 35.89 51.74
Support Level $1.27 $2.23
Resistance Level $2.22 $2.45
Average True Range (ATR) 0.11 0.12
MACD 0.02 -0.02
Stochastic Oscillator 17.00 17.47

Price Performance

Historical Comparison
AMS
KPRX

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: